ARDELYX, INC. (ARDX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$31.2M
Cash & Equivalents
$32.2M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$1,304M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase3 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05905926 | Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C | PHASE3 | Enrolling By Invitation | 150 |
| NCT05643534 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | PHASE3 | Active Not Recruiting | 180 |
| NCT06553547 | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs | PHASE2 | Active Not Recruiting | 72 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.